Navigation Links
Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
Date:9/17/2007

l studies with G4544 will be to establish its bioequivalence with the intravenous product, potentially enabling rapid regulatory approval of the oral formulation. Genta holds or has exclusively licensed the intellectual property related to G4544.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named- patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or produc
'/>"/>

SOURCE Genta Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
7. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
8. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 27, 2015 /CNW/ - Export Development Canada (EDC) ... financing for Montreal,s Valeant Pharmaceuticals ... multinational pharmaceutical company. The loan is ... facility that Valeant is using to fund the repayment ... a leading gastrointestinal pharmaceutical company based in the US. ...
(Date:5/26/2015)...  The National Association of Boards of Pharmacy ® ... general availability for the .pharmacy domain begins June 3, ... may apply for .pharmacy domain names. The ... NABP has approved more than 300 .pharmacy domain names ... NABP created the .pharmacy TLD to provide consumers worldwide ...
(Date:5/26/2015)... 2015  AbbVie (NYSE: ABBV ) presented ... of its investigational, all-oral, interferon (IFN)- and ribavirin ... the Annual Meeting of the Japan Society of ... 1 GIFT-I evaluated genotype 1b (GT1b) chronic ... and without cirrhosis, who were either treatment-naïve or ...
Breaking Medicine Technology:EDC provides Valeant Pharmaceuticals with USD 67.5 M to support recent Salix Pharmaceuticals acquisition 2General Availability for .Pharmacy Domain Names Begins June 3, 2015 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6
... ANGELES , Aug. 5 B. Braun Medical Inc. (B. Braun) ... gain premier access to customized, evidence-based drug libraries provided by the Zynx Health ... , , , ... , , , ...
... Aug. 5 Decision Resources, one of the ... healthcare issues, finds that, in first- and second-line treatment ... nearly 70 percent of surveyed infectious disease specialists and ... use Medarex/Merck,s CDA1 and CDB1, one year after the ...
Cached Medicine Technology:B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 2B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 3B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 4B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 5B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 6In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1 2In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1 3
(Date:5/26/2015)... Francisco, CA (PRWEB) May 27, 2015 ... and beautiful technology for women, today announces the ... that monitors women’s stress, sleep, activity and ovulation. ... jewelry with innovative health tracking technolo- gy, particularly ... stress levels, to provide women with lifestyle data ...
(Date:5/26/2015)... BROOK, Ill. (PRWEB) May 26, 2015 ... be an early marker of specific types of Alzheimer’s ... a new study published in the journal Radiology. ... Agosta, M.D., Ph.D., co-author of the study conducted at ... Milan, Italy. “However, white matter damage has a central ...
(Date:5/26/2015)... May 27, 2015 Visiting Nurse Association of ... at the American Cancer Society’s annual Relay for Life fundraiser. ... 12:00AM at Mennen Sports Arena, 161 East Hanover Ave, Morristown, ... the track to raise money and awareness to help the ... , According to the ACS, it is estimated that more ...
(Date:5/26/2015)... 2015 Securityhunter has been ... the United States Department of Health and Human Services ... The MATOC was awarded through the General Services Administration ... the PSC, which is a fee-for-service agency. The award ... options, and is an enterprise–wide physical security and security ...
(Date:5/26/2015)... ANGELES (PRWEB) May 27, 2015 Readers ... processes may find help in author Chester Litvin ... Psychoconduction : Litvin’s Code” (published by Trafford Publishing). , ... new approach for stimulating the brain. This book will ... to reeducate their sensory brain cells . He ...
Breaking Medicine News(10 mins):Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 2Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 3Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 3Health News:North Jersey Home Care Agency Supports Relay for Life Fundraiser 2Health News:Securityhunter Has Been Awarded a Multiple Award Task Order Contract (MATOC) by the Department of Health and Human Services 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 3
... , FRIDAY, Jan. 22 (HealthDay News) -- If you,re ready to ... potty training may be between the second and third birthdays. , ... window for moving your child out of diapers. Children who were ... incontinence -- daytime wetting and bed-wetting -- between ages 4 and ...
... physical and mental benefits as people grow old , FRIDAY, ... and gunning down bad guys might not sound like things ... , But they might want to start, some experts on ... have the potential to help seniors age more gracefully, keeping ...
... Drug Administration has approved the drug fampridine-SR for the treatment ... Medical Center (URMC) have been evaluating the effects of the ... the first medication shown to enhance some neurological functions in ... the way for today,s action by the FDA. ...
... Society report outlines 21 challenges and needs for global tobacco ... and expertise needed to reduce the rising tide of tobacco ... are the target of the multinational tobacco industry. The report ... issue of CA: A Cancer Journal for Clinicians . ...
... most women, having a baby is a joyful experience. But ... by grief, anxiety and depression. Global figures suggest that between ... first time are struck by depression. For the second birth, ... Kristin Akerjordet at the University of Stavanger in Norway, surveyed ...
... 2010) -- Weill Cornell Medical College has established a ... diverse and medically underserved communities in New York City. ... and Community Engagement (CEDREC) was created through an $8 ... and Health Disparities (NCMHD), a division of the National ...
Cached Medicine News:Health News: Potty Training Best Between Ages 2 and 3 2Health News: Potty Training Best Between Ages 2 and 3 3Health News: Potty Training Best Between Ages 2 and 3 4Health News:Video Gaming Just Might Fight Aging 2Health News:Video Gaming Just Might Fight Aging 3Health News:Researchers welcome new multiple sclerosis drug 2Health News:Researchers welcome new multiple sclerosis drug 3Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Emotions should be taken seriously 2Health News:Emotions should be taken seriously 3Health News:National Center on Minority Health and Health Disparities awards $8 million to Weill Cornell 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: